| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbadc41aa91592752369d88100f96411 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-36 |
| filingDate |
2004-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51ba7f4c8d9aaceeb0f458861f9785f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2e0ed07001f0803eef37a8360b8e393
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0eba2b11b575897ef0486800a1c96498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eddc1be10af4407025b6372728cd96a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfc1eeb19ca527cfa0021f78557170ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcf638c7075b38adda5cc3a90a724582 |
| publicationDate |
2006-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1667718-A2 |
| titleOfInvention |
Method of promoting graft survival with anti-tissue factor antibodies |
| abstract |
The present invention is directed to a method of using function blocking tissue factor antibodies to enhance graft survival in mammals. Function blocking antibodies having the effect of blocking activated tissue factor (TF), TF and its Logan FVII as either the inactive TF:FVII or active TF:FVIIa complex, or block the formation f the TF:FVIIa:FX ternary complex are useful in the method. These properties provide a therapy that has directed action towards thrombotic events involving tissue-plasma interactions but does not prevent the intrinsic pathway for coagulation. Activated TF arises on cells, tissues, and organs during or after transplantation and is a major cause of graft loss. |
| priorityDate |
2003-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |